"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 3 | 2 | 5 |
| 2005 | 4 | 2 | 6 |
| 2006 | 2 | 1 | 3 |
| 2007 | 5 | 0 | 5 |
| 2008 | 3 | 2 | 5 |
| 2009 | 3 | 4 | 7 |
| 2010 | 8 | 7 | 15 |
| 2011 | 4 | 1 | 5 |
| 2012 | 6 | 1 | 7 |
| 2013 | 9 | 5 | 14 |
| 2014 | 8 | 7 | 15 |
| 2015 | 11 | 5 | 16 |
| 2016 | 5 | 2 | 7 |
| 2017 | 7 | 4 | 11 |
| 2018 | 2 | 2 | 4 |
| 2019 | 4 | 1 | 5 |
| 2020 | 2 | 3 | 5 |
| 2021 | 1 | 3 | 4 |
| 2022 | 2 | 3 | 5 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 1 | 3 |
| 2025 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Clinical and Demographic Characteristics Associated With Diabetes Remission in Six Integrated Health Care Systems: A Retrospective Cohort Study. Diabetes Care. 2025 Oct 01; 48(10):1737-1743.
-
GLP-1RA comparative effectiveness against dementia onset relative to other antidiabetic medications in a large, multi-site cohort of patients with type 2 diabetes. Alzheimers Dement. 2025 Sep; 21(9):e70621.
-
Diabetes Deprescribing in Older Adults: A Randomized Clinical Trial. JAMA Intern Med. 2025 Aug 01; 185(8):926-935.
-
The association of weight status with glycemic control, diabetes related complications and anti-hyperglycemic medication use in patients with type 2 diabetes mellitus: The results of the Australian National Diabetes Audit (ANDA) 2015-2022. Diabetes Res Clin Pract. 2025 Aug; 226:112333.
-
Expanded care planning paradigm for older adults with type 2 diabetes: Rationale, design, and protocol of the PREPARE for Your Diabetes Care randomized trial. Contemp Clin Trials. 2025 Jun; 153:107913.
-
Structural innovation for hypoglycemia prevention in high-risk patients with type 2 diabetes: Design and implementation of a pragmatic, randomized, quality improvement trial. Contemp Clin Trials. 2025 May; 152:107885.
-
Sex-Specific Cardiovascular Risk Factors and Treatment in Females With T2DM and CVD: Developments and Knowledge Gaps. J Clin Endocrinol Metab. 2024 Nov 18; 109(12):e2167-e2177.
-
Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis. BMJ Open Diabetes Res Care. 2024 May 06; 12(3).
-
Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2024 May; 177(5):658-666.
-
Heterogeneous Treatment Effects of Intensive Glycemic Control on Kidney Microvascular Outcomes and Mortality in ACCORD. J Am Soc Nephrol. 2024 02 01; 35(2):216-228.